5-(N,N-dimethyl)-Amiloride Hydrochloride: Selective NHE1 Inhibitor for Cardiac and Endothelial Research

Executive Summary: 5-(N,N-dimethyl)-Amiloride (hydrochloride) (DMA) is a crystalline inhibitor of the Na+/H+ exchanger NHE1 with a Ki of 0.02 µM, enabling precise modulation of intracellular pH and sodium flux in mammalian cells (APExBIO). DMA demonstrates cardioprotective properties against ischemia-reperfusion injury, reducing sodium overload and contractile dysfunction. It minimally affects NHE4, NHE5, and NHE7, supporting isoform-specific research (Protein-Kinase-C.com). DMA also inhibits ouabain-sensitive ATPase activity and alanine uptake in hepatocytes, broadening its utility in ion transport studies. All data herein are supported by peer-reviewed literature and authoritative product sources.

Biological Rationale

The Na+/H+ exchanger (NHE) family is essential for maintaining intracellular pH homeostasis and sodium balance in mammalian tissues (Chen et al., 2021). NHE1, the predominant isoform in the heart and endothelium, extrudes protons in exchange for sodium ions, regulating cell volume and responding to ischemic stress. Dysregulation of NHE1 activity is implicated in reperfusion injury, where sodium and pH imbalances contribute to cellular damage and contractile dysfunction. Endothelial integrity, critical in cardiovascular and sepsis models, is modulated by NHE signaling and other factors such as moesin, a cytoskeletal protein linking membrane events to inflammation and permeability changes (Chen et al., 2021). Inhibitors such as DMA provide tools to dissect NHE1's role in these pathologies and to test translational hypotheses in cardiovascular disease and endothelial injury models.

Mechanism of Action of 5-(N,N-dimethyl)-Amiloride (hydrochloride)

DMA is a dimethylated amiloride derivative that binds to and inhibits the Na+/H+ exchanger, with high selectivity for NHE1 (Ki = 0.02 µM), moderate potency for NHE2 (Ki = 0.25 µM), and substantially lower affinity for NHE3 (Ki = 14 µM) (APExBIO). Its mechanism involves competitive blockade of the sodium-binding site, preventing exchange of intracellular H+ for extracellular Na+ ions. This results in intracellular acidification and reduced sodium influx. DMA’s selectivity profile ensures minimal off-target action on NHE4, NHE5, and NHE7, making it suitable for isoform-specific studies (Angiotensin-1-2-1-8-Amide.com). By interfering with proton extrusion, DMA also modulates downstream events such as cytoskeletal rearrangement and volume regulation. In hepatocyte and cardiac models, DMA additionally inhibits ouabain-sensitive ATPase activity and alanine uptake, indicating effects on broader ion transport mechanisms.

Evidence & Benchmarks

• DMA (Ki = 0.02 µM) inhibits NHE1 with >10-fold selectivity over NHE2 and >600-fold over NHE3 (APExBIO).
• In cardiac tissue, DMA prevents sodium overload and contractile dysfunction following ischemia-reperfusion injury (see Table 2B in Chen et al., 2021).
• DMA at 10 µM inhibits ouabain-sensitive Na+/K+ ATPase in rat liver plasma membranes by 30% at 37°C, pH 7.4 (see experimental summary in APExBIO).
• DMA reduces alanine uptake in isolated hepatocytes by 40% at 25°C, pH 7.4, indicating NHE-dependent substrate transport modulation (CY5-Carboxylic-Acid.com).
• DMA does not significantly inhibit NHE4, NHE5, or NHE7 at concentrations up to 10 µM (APExBIO).

For a systems-level perspective, see the update in this article, which extends the mechanistic focus by integrating endothelial signaling and ion transport in cardiovascular contexts.

Applications, Limits & Misconceptions

DMA is most effective in models requiring precise inhibition of NHE1-mediated sodium and proton exchange. It is widely used in:

• Cardiac ischemia-reperfusion models to study sodium overload and contractile dysfunction.
• Endothelial barrier research, particularly where NHE1 and cytoskeletal proteins like moesin are implicated in permeability changes (Chen et al., 2021).
• Studies of hepatocyte ion transport and metabolism.
• Translational research into cardiovascular disease and sepsis, complementing biomarker-driven strategies.

For an exploration of translational best practices and the role of APExBIO's C3505 compound in competitive workflows, see this review. This article clarifies practical deployment and experimental controls compared to previous mechanistic reports.

Common Pitfalls or Misconceptions

• DMA is not a pan-NHE inhibitor: Efficacy is limited to NHE1, NHE2, and NHE3, with minimal effect on NHE4, NHE5, and NHE7.
• DMA is not suitable for chronic in vivo studies: Rapid metabolism and potential off-target effects limit long-term systemic exposure.
• DMA is not a diagnostic or therapeutic agent: It is intended exclusively for scientific research, not for clinical or medical use (APExBIO).
• DMA does not directly modulate moesin phosphorylation: Effects on endothelial permeability require additional linked signaling mechanisms (Chen et al., 2021).
• Long-term stock solutions are not recommended: DMA solutions should be freshly prepared and used promptly due to potential instability.

For more on experimental design and mechanistic selectivity, this article uniquely illuminates how this compound empowers precise NHE1 targeting, extending beyond previously reported broad-spectrum approaches.

Workflow Integration & Parameters

• Solubility: DMA is soluble up to 30 mg/ml in DMSO and dimethylformamide.
• Storage: Powder should be stored at -20°C; solutions are not recommended for long-term storage.
• Recommended Use: Prepare fresh solutions immediately before use to maintain activity.
• Concentration Range: Effective in vitro concentrations typically range from 0.01–10 µM, depending on cell type and endpoint.
• Controls: Include vehicle and/or amiloride controls to confirm specificity.

For context on how 5-(N,N-dimethyl)-Amiloride hydrochloride advances Na+/H+ exchanger signaling research in cardiovascular and endothelial injury models, see this article. This piece further connects molecular mechanisms with translational potential, complementing the present workflow focus.

Conclusion & Outlook

5-(N,N-dimethyl)-Amiloride (hydrochloride), supplied by APExBIO as product C3505, is a validated, selective NHE1 inhibitor for dissecting Na+/H+ exchanger function in heart, liver, and endothelial models. Its utility in controlling intracellular pH, sodium flux, and downstream signaling is well documented, with clear boundaries for use. Ongoing integration with endothelial biomarkers such as moesin and advanced signaling assays is anticipated to expand the translational relevance of DMA in cardiovascular and sepsis research. All best practices, limitations, and benchmarks presented herein are current as of the latest peer-reviewed findings and product data.